Landec

Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Maria, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lifecore Biomedical, Inc. is a contract development and manufacturing organization, which engages in the provision of differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It operates through the following business segments: Lifecore, Curation Foods, and Others. The Lifecore segment focuses on selling products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the Ophthalmic, Orthopedic and other markets. The Curation Foods segment is focused on innovating and distributing plant-based foods with 100% clean ingredients to retail, club and foodservice channels. The Others segment is Corporate, which includes corporate general and administrative expenses, Non Lifecore and non-Curation Food interest income, interest expense, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Chaska, MN.

CHASKA, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Lifecore” or the “Company”), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. (“Lifecore”) and Curation Foods, Inc. (“Curation Foods”), – today announced that Jim Hall, CEO of Landec Corporation & President of Lifecore, and John Morberg, CFO will be hosting a fireside chat at the Stephens Annual Investment Conference in Nashville, TN.

Lifecore Biomedical to Participate in the Stephens Annual Investment Conference on Thursday, November 17, 2022

Landec Corporation (NASDAQ:LNDC ) Q1 2023 Earnings Conference Call October 6, 2022 8:00 AM ET Company Participants Jeff Sonnek - Investor Relations, ICR Jim Hall - Chief Executive Officer John Morberg - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Mark Smith - Lake Street Capital Markets Mike Petusky - Barrington Research Mitch Pinheiro - Sturdivant & Company Operator Good morning and thank you for joining Landec's Fiscal 2023 First Quarter Earnings Call. During the presentation, all participants will be in a listen-only mode.

Landec Corporation (LNDC) Q1 2023 Earnings Call Transcript

Landec (LNDC) delivered earnings and revenue surprises of -166.67% and 1.89%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?

Landec (LNDC) Reports Q1 Loss, Tops Revenue Estimates

Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year period Lifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year period Reiterates fiscal 2023 full year guidance for Lifecore Corporate rebranding to Lifecore Biomedical continues to progress

Landec Corporation Reports First Quarter Fiscal Year 2023 Results

SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Landec” or the “Company”), a diversified health and wellness company focused on its growing Lifecore Biomedical (“Lifecore”) business – a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced a change to its previously announced fiscal 2023 first quarter earnings conference call date in recognition of Yom Kippur.

Landec Corporation Revises First Quarter 2023 Earnings Conference Call for October 6, 2022 at 8:00 a.m. ET

SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Landec” or the “Company”), a diversified health and wellness company focused on its growing Lifecore Biomedical (“Lifecore”) business – a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced that it will host a conference call to discuss fiscal 2023 first quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The webcast will be available for 30 days.

Landec Corporation Sets First Quarter 2023 Earnings Conference Call for October 5, 2022 at 2:00 p.m. PT

Avantis U.S. Small Cap Value ETF

Diversified Healthcare Trust

Movado Group

Tenable Holdings Inc

Vanguard S&P Small-Cap 600 Growth ETF

Vista Oil & Gas SAB de CV

While broader markets face continued pressure amid recession fears, small-cap stocks stand out as an undervalued segment of the stock market. The Russell 2000 index, the popular benchmark for small-cap stocks, is currently down 18% over the past year.

7 Small-Cap Stocks to Buy Before September Ends

SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Landec Corp. (NASDAQ: LNDC) (the “Company”) announced today that it received a notice (“Notice”) on September 2, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company failed to timely file its Annual Report on Form 10-K for the year ended May 29, 2022 (the “Form 10-K”) with the Securities and Exchange Commission.

Landec Corp. Receives Notice from Nasdaq Regarding Delayed Annual Report

Landec Corporation (NASDAQ:LNDC ) Q4 2022 Earnings Conference Call August 10, 2022 5:00 PM ET Company Participants Jeff Sonnek - Investor Relations, ICR Jim Hall - Chief Executive Officer John Morberg - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Mike Petusky - Barrington Research Connor Jensen - Lake Street Capital Markets Operator Good afternoon and thank you for joining Landec's Fiscal 2022 Fourth Quarter Earnings Call. During the presentation, all participants will be in a listen-only mode.

Landec Corporation (LNDC) CEO Jim Hall on Q4 2022 Results - Earnings Call Transcript

Recently announced intent to rename and rebrand to Lifecore Biomedical, along with leadership and Board changes

Landec Corporation Reports Fourth Quarter and Full Fiscal Year 2022 Results

Landec expected to rename and rebrand to Lifecore Biomedical and update Nasdaq ticker symbol

Landec Corporation Announces Intention to Become Lifecore Biomedical

SANTA MARIA, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC) (“Landec” or the “Company”), a diversified health and wellness company focused on its growing Lifecore Biomedical (“Lifecore”) business – a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced that it will host a conference call to discuss fiscal 2022 fourth quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The webcast will be available for 30 days.

Landec Corporation Sets Fourth Quarter 2022 Earnings Conference Call for August 10, 2022 at 2:00 p.m. PT

DENVER--(BUSINESS WIRE)--Custom Made Meals (CMM), a leading national provider of fresh, ready-to-cook (RTC) entrees, appetizers, and sides for the meat and deli departments of retail grocery and club stores, announced today that it has appointed Molly Montgomery as CEO, effective today. Ms. Montgomery has served on the CMM Board of Directors since it was acquired by Stellex Capital Management LLC (Stellex) in May of 2021 and will continue to serve on the board in her new role. Stellex is a midd

Custom Made Meals Appoints Molly Montgomery as Chief Executive Officer

Landec Corporation (LNDC) CEO Albert Bolles on Q3 2022 Results - Earnings Call Transcript

Lifecore segment revenues increased 27.9% in fiscal third quarter, as compared to prior year period

Landec Corporation Reports Third Quarter Fiscal Year 2022 Results

Landec Corporation (LNDC) CEO Albert Bolles on Q2 2022 Results - Earnings Call Transcript

Landec (LNDC) delivered earnings and revenue surprises of -212.50% and 2.16%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?

Landec (LNDC) Reports Q2 Loss, Misses Revenue Estimates

Reiterates Fiscal 2022 Guidance for Lifecore

Landec Corporation Reports Second Quarter Fiscal Year 2022 Results

Landec (LNDC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Landec (LNDC) Q2 Earnings Expected to Decline

Landec (LNDC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Landec (LNDC) Stock Jumps 13%: Will It Continue to Soar?

Landec Corp (NASDAQ: LNDC) has completed the sale of its Curation Food's fresh packaged salads and vegetables business for $73.5 million in cash to Taylor Farms Retail Inc. The company plans to use net proceeds to repay borrowings under its credit facility.

Landec Closes Sale Of Curation Food's Fresh Packaged Salads, Vegetables Business

SALINAS, Calif., Dec. 14, 2021 /PRNewswire/ -- Taylor Farms announces the acquisition of Curation Foods' fresh packaged salads, green beans and fresh cut vegetables business from Landec Corporation (Nasdaq: LNDC), effective December 13 th, 2021.

Taylor Farms Acquires Curation Foods' Fresh Packaged Salads, Green Beans and Fresh Cut Vegetables Business from Landec Corporation

Strategic sale results in a CDMO-focused company aligned with attractive growth categories and end markets Net proceeds from the sale will be allocated towards debt pay down, resulting in significant deleveraging Announces fiscal second quarter earnings call on January 5, 2022

Landec Corporation Announces Sale of Curation Foods' Fresh Packaged Salads and Vegetables Business for $73.5 Million in Cash

Landec's most relevant business segment focuses on the sale of fresh packaged salads and vegetables. However, the company also sells avocado products and sodium hyaluronate-based products. I studied the sales growth reported by Lifecore. In 2021, this business segment reported a sales growth of 14%.

Optimistic About Landec's Strategic Initiatives And Sodium Hyaluronate Products

The company failed to meet earnings expectations, causing a sharp sell-off.

News for Landec Stock (LNDC)